Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

uPAR as anti-cancer target: evaluation of biomarker potential, histological localization, and antibody-based therapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Interferon alpha for treatment of chronic myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Interferon-α treatment in systemic mastocytosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Interferon-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Status and perspectives

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Interferon treatment in patients with hypereosinophilia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prognostic impact of histological review of high-grade endometrial carcinomas in a large Danish cohort

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Plasma IL-8 and ICOSLG as prognostic biomarkers in glioblastoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Degradation of proteins in the extracellular matrix is crucial for the multistep process of cancer invasion and metastasis. Compelling evidence has demonstrated the urokinase receptor (uPAR) and its cognate ligand, the urokinase plasminogen activator (uPA), to play critical roles in the concerted action of several proteolytic systems in generation of a high proteolytic potential required for tissue remodeling processes. uPAR is additionally cleaved by uPA on the cell surface, liberating domain I, resulting in abrogated pericellular proteolysis. The expression of both uPAR and uPA is significantly up-regulated during cancer progression and is primarily confined to the tumor-associated stromal compartment. Furthermore, both uPAR and uPA have proven to be prognostic markers in several types of cancer; high levels indicating poor survival. The cleaved forms of uPAR are also prognostic markers, and a potential diagnostic and predictive impact of the different uPAR forms has been reported. Hence, pericellular proteolysis seems to be a suitable target for anti-cancer therapy and numerous approaches have been pursued. Targeting of this process may be achieved by preventing the binding of uPA to uPAR on the cell surface and/or by direct inhibition of the catalytic activity of uPA. Both strategies have been pursued and inhibition of these functions has shown effect in xenogenic cancer models. Pericellular proteolysis has also been inhibited in vivo in mouse models of wound healing and hepatic fibrinolysis using mouse monoclonal antibodies (mAbs) against mouse uPA or uPAR. These reagents will target uPA and uPAR in both stromal cells and cancer cells, and their therapeutic potential can now be assessed in syngenic mouse cancer models.
OriginalsprogEngelsk
TidsskriftCurrent Drug Targets
Vol/bind12
Udgave nummer12
Sider (fra-til)1744-60
Antal sider17
ISSN1389-4501
StatusUdgivet - 2011

ID: 33286119